AKT1 and cancer: Similarly, nanoparticles targeting the PI3K/Akt pathway with surface-modified PI3K inhibitors (e.g., LY294002) could synergistically block PI3K/Akt signaling, thereby enhancing GA’s inhibition of the PI3K/Akt/mTOR pathway, a pathway frequently dysregulated in malignant tumors.